MX2019005934A - Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac). - Google Patents

Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).

Info

Publication number
MX2019005934A
MX2019005934A MX2019005934A MX2019005934A MX2019005934A MX 2019005934 A MX2019005934 A MX 2019005934A MX 2019005934 A MX2019005934 A MX 2019005934A MX 2019005934 A MX2019005934 A MX 2019005934A MX 2019005934 A MX2019005934 A MX 2019005934A
Authority
MX
Mexico
Prior art keywords
compounds
benzodiazolium
enac inhibitors
conditions
enac
Prior art date
Application number
MX2019005934A
Other languages
English (en)
Inventor
Mccarthy Clive
Went Naomi
David Hargrave Jonathan
Alexander Hay Duncan
Beauregard Schofield Thomas
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of MX2019005934A publication Critical patent/MX2019005934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de formula general (I)(ver formula) (I) en donde R1, R2, R3, R4, R5 y X son como se definen en la presente son inhibidores del canal de sodio epitelial (ENaC) y son utiles para el tratamiento o prevención de enfermedades y condiciones respiratorias, condiciones de la piel y condiciones oculares.
MX2019005934A 2016-11-22 2017-11-22 Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac). MX2019005934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (1)

Publication Number Publication Date
MX2019005934A true MX2019005934A (es) 2019-11-12

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005934A MX2019005934A (es) 2016-11-22 2017-11-22 Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).

Country Status (21)

Country Link
US (3) US10941149B2 (es)
EP (1) EP3544981B1 (es)
JP (1) JP6980014B2 (es)
KR (1) KR102517273B1 (es)
CN (1) CN110214141B (es)
AU (1) AU2017364308B2 (es)
BR (1) BR112019009864A2 (es)
CA (1) CA3043132A1 (es)
DK (1) DK3544981T3 (es)
EA (1) EA039607B1 (es)
ES (1) ES2890226T3 (es)
GB (1) GB201619694D0 (es)
HU (1) HUE055692T2 (es)
IL (1) IL266745B (es)
MA (1) MA46878A (es)
MX (1) MX2019005934A (es)
PL (1) PL3544981T3 (es)
PT (1) PT3544981T (es)
TW (1) TWI756305B (es)
WO (1) WO2018096325A1 (es)
ZA (1) ZA201902710B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) * 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
MA56186A (fr) 2019-06-12 2022-04-20 Tmem16A Ltd Composés pour le traitement d'une maladie respiratoire
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
TW202237090A (zh) 2020-12-11 2022-10-01 英商Ｔｍｅｍ16Ａ有限公司 治療呼吸道疾病之化合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7317013B2 (en) 2003-08-18 2008-01-08 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
US7375107B2 (en) 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
RU2006118312A (ru) * 2003-10-28 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бензимидазолы, полезные в качестве модуляторов ионных каналов
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
JP5066514B2 (ja) * 2005-03-14 2012-11-07 ハイ ポイント ファーマシューティカルズ，エルエルシー ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
AU2009246799B2 (en) 2008-02-26 2014-02-27 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
JP2011520831A (ja) 2008-05-13 2011-07-21 ノバルティス アーゲー ３，５−ジアミノ−６−クロロ−ピラジン−２−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) * 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US8759349B2 (en) 2011-11-02 2014-06-24 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
EP2855435B1 (en) 2012-05-29 2018-04-11 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
JP6072920B2 (ja) 2012-09-24 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
WO2015003083A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
WO2015007517A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel tetra- and pentasubstituted benzimidazolium compounds
EP3022198B1 (en) 2013-07-15 2019-09-11 Boehringer Ingelheim International GmbH Novel 5-substituted benzimidazolium compounds
WO2015007519A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel benzimidazolium compounds
WO2015018754A1 (en) 2013-08-08 2015-02-12 Boehringer Ingelheim International Gmbh Novel pyrazine amide compounds
WO2016113167A1 (en) * 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US9981954B2 (en) 2015-01-12 2018-05-29 Boehringer Ingelheim International Gmbh 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors
JP6667537B2 (ja) 2015-01-12 2020-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な四置換及び五置換ベンズイミダゾリウム化合物
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
DK3298022T3 (da) 2015-08-20 2019-08-26 Boehringer Ingelheim Int Nye annelerede phenoxyacetamider
EP3337483B1 (en) 2015-08-20 2019-10-09 Boehringer Ingelheim International GmbH Novel annelated benzamides
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
DK3544981T3 (da) 2021-09-20
KR20190084076A (ko) 2019-07-15
PL3544981T3 (pl) 2021-12-20
ZA201902710B (en) 2021-10-27
CN110214141A (zh) 2019-09-06
TWI756305B (zh) 2022-03-01
IL266745B (en) 2021-12-01
US10941149B2 (en) 2021-03-09
MA46878A (fr) 2019-10-02
US20240067653A1 (en) 2024-02-29
EP3544981A1 (en) 2019-10-02
JP2019535747A (ja) 2019-12-12
TW201833111A (zh) 2018-09-16
US20210147432A1 (en) 2021-05-20
HUE055692T2 (hu) 2021-12-28
WO2018096325A1 (en) 2018-05-31
EP3544981B1 (en) 2021-06-23
US20190315757A1 (en) 2019-10-17
KR102517273B1 (ko) 2023-04-03
US11739094B2 (en) 2023-08-29
JP6980014B2 (ja) 2021-12-15
IL266745A (en) 2019-07-31
EA201991253A1 (ru) 2019-11-29
CN110214141B (zh) 2022-05-31
AU2017364308B2 (en) 2021-03-11
GB201619694D0 (en) 2017-01-04
EA039607B1 (ru) 2022-02-16
AU2017364308A1 (en) 2019-05-23
BR112019009864A2 (pt) 2019-08-27
PT3544981T (pt) 2021-09-23
ES2890226T3 (es) 2022-01-18
CA3043132A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
MX2023001876A (es) Derivados de rapamicina.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12020500655A1 (en) Compounds
MX2018006207A (es) Compuestos heterociclicos como inmunomoduladores.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
PH12017502363A1 (en) Brk inhibitory compound
MX2017004234A (es) Inhibidor del egfr y preparacion y aplicacion del mismo.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
MY197698A (en) Oxysterols and methods of use thereof
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof